Unequal by Design: The Hidden Financial Burden Women Carry for Sexual Health Care
For decades, the conversation about sexual health coverage in the United States has quietly favored one gender. While men with erectile dysfunction can often walk into a pharmacy and fill a prescription for sildenafil — sometimes at under $20 per pill through generic programs — women seeking treatment for hypoactive sexual desire disorder (HSDD) or other forms of female sexual dysfunction routinely face insurance denials, high out-of-pocket costs, and a pharmaceutical marketplace that has yet to achieve anything close to pricing parity. The disparity is not incidental. It is structural.
What Insurance Actually Covers — and What It Doesn't
Medicare Part D, most Medicaid plans, and the majority of commercial insurance policies have historically covered erectile dysfunction medications with varying degrees of generosity. While coverage is not universal, the pathway to reimbursement is well-established, and the generic landscape has made these drugs dramatically more affordable over time.
Contrast that with the two FDA-approved medications for female sexual dysfunction currently on the US market: flibanserin (Addyi), approved in 2015 for premenopausal women with HSDD, and bremelanotide (Vyleesi), approved in 2019. Both drugs carry list prices in the hundreds of dollars per month or per dose, and insurance coverage remains inconsistent at best. Many insurers classify these medications as lifestyle drugs — the same designation historically applied to erectile dysfunction treatments — yet the practical reality of coverage has not followed the same trajectory.
A 2022 analysis found that fewer than 40 percent of commercial insurance plans offered any coverage for flibanserin, compared to substantially higher coverage rates for PDE5 inhibitors used to treat erectile dysfunction. The result is that women are far more likely to pay entirely out of pocket, or to forgo treatment altogether.
The Lifestyle Drug Label: A Double Standard With Real Consequences
The "lifestyle drug" classification is one of the most consequential — and arguably most gendered — designations in American pharmaceutical policy. When erectile dysfunction medications first entered the market in the late 1990s, advocacy groups, medical associations, and pharmaceutical lobbying efforts successfully pushed back against blanket exclusions, framing erectile dysfunction as a legitimate medical condition deserving of coverage. That framing effort was largely successful.
Female sexual dysfunction, by contrast, has not benefited from the same institutional momentum. Critics point to a persistent cultural narrative that frames women's sexual desire as inherently more psychological, more variable, and less medically urgent than men's. This narrative has consequences at the insurance underwriting level. When a condition is perceived as elective or subjective, coverage decisions reflect that bias — regardless of what the clinical literature actually says.
HSDD is a diagnosable condition with validated assessment tools and documented impacts on quality of life, relationships, and psychological well-being. The science is not in dispute. The coverage, however, remains elusive.
Out-of-Pocket Costs: Running the Numbers
For women who do pursue treatment without insurance support, the financial reality is sobering. Flibanserin carries a retail price of approximately $800 to $900 per month without coverage. Vyleesi, administered as a self-injection before anticipated sexual activity, lists at roughly $900 per dose at many pharmacies. Patient assistance programs exist, and manufacturer coupons can reduce costs significantly, but these programs are not universally accessible, may have income eligibility requirements, and do not represent a sustainable long-term solution.
Generic sildenafil, meanwhile, is available through discount pharmacy programs for as little as $10 to $30 for a 30-day supply. The pricing gap between the most affordable erectile dysfunction treatment and the most affordable FDA-approved female sexual dysfunction treatment is not measured in percentage points — it is measured in orders of magnitude.
Additional costs compound the disparity. Women seeking treatment for sexual dysfunction often navigate a longer diagnostic journey, requiring multiple specialist visits before receiving a prescription. Pelvic floor physical therapy, vaginal hormone therapies, and compounded formulations — all commonly recommended as part of comprehensive care — carry their own costs, many of which are also poorly reimbursed.
Why This Gap Persists
Several intersecting factors sustain the coverage disparity. First, the pharmaceutical pipeline for female sexual health has historically been thin. Fewer approved drugs means less market competition, which means higher prices and less insurer incentive to develop robust coverage pathways. Second, the advocacy infrastructure that successfully lobbied for erectile dysfunction coverage was built over years with significant industry investment. The equivalent infrastructure for women's sexual health is younger and still developing.
Third — and perhaps most fundamentally — the medical establishment has been slower to validate female sexual dysfunction as a priority. When a condition lacks visibility in clinical guidelines, insurers have more latitude to deny coverage without meaningful pushback.
What Equitable Access Would Actually Look Like
Advocates and clinicians working in women's sexual health have outlined a clear set of priorities. Insurance parity legislation that applies the same coverage standards to female sexual dysfunction medications as to erectile dysfunction treatments would represent a meaningful first step. Transparent prior authorization processes, with clear clinical criteria rather than blanket exclusions, would reduce the burden on both patients and prescribers.
At the pharmaceutical level, continued investment in generic pathways and manufacturer assistance programs can help bridge the gap in the near term. But these are stopgaps, not solutions.
Ultimately, the financial barriers women face in accessing sexual health care are a reflection of how the healthcare system values female sexual function. Until that valuation changes — in policy, in insurance design, and in clinical culture — women will continue paying a premium for care that their male counterparts receive as a matter of course.
The cost of that inequality is not only financial. It is measured in untreated conditions, in silenced conversations, and in the persistent message that women's sexual well-being is a luxury rather than a healthcare right.
